WHO Granted Prequalification to Cervavac HPV Vaccine
The international approval allows global agencies to distribute this vaccine to individuals aged 9 to 26.
Updated on Oct. 5, 2026 in Cancer
Live Poll
Should international health agencies prioritize the certification of vaccines developed in emerging economies?
The World Health Organization has officially granted prequalification status to the Cervavac HPV vaccine, developed by the Serum Institute of India. This milestone enables international agencies to procure and distribute the shot to prevent various cancers and genital warts.
Why it matters
This approval significantly expands global access to HPV vaccination by validating a new, widely available product for international health programs. It provides a reliable pathway for regions to protect younger populations against cervical, anal, and other HPV-linked cancers.
The WHO confirmed the vaccine's safety and efficacy standards for widespread distribution, marking the 32nd prequalification awarded to the Serum Institute of India. The approval process evaluated the vaccine's ability to target HPV types 6, 11, 16, and 18, though long-term programmatic outcomes in global settings remain under investigation.
The players
World Health Organization
The United Nations agency responsible for international public health that establishes global standards for vaccine safety and procurement.
Serum Institute of India
A major global vaccine manufacturer based in India that develops and produces affordable immunizations for infectious diseases.
The details
Cervavac targets HPV types 6 and 11, which cause genital warts, and types 16 and 18, which are linked to cervical, vulvar, vaginal, and anal cancers. The vaccine is administered via intramuscular injection for individuals aged 9 to 26 years. Younger recipients aged 9 to 14 follow a two-dose schedule at 0 and 6 months, while those aged 15 to 26 require a three-dose series at 0, 2, and 6 months.
Timeline
October 5, 2026: WHO granted prequalification status to the Cervavac vaccine.
Health Landscape
This approval integrates Cervavac into the global immunizations pipeline alongside established international standards. It reflects the ongoing effort to expand the reach of HPV preventive measures by diversifying the portfolio of prequalified products available to health agencies worldwide.
This development ensures that an additional, verified vaccine option will be available for HPV prevention across international health systems. If you have questions about the recommended vaccination schedule for you or your child, it is a key topic to discuss with your physician.
The takeaway
The WHO's approval of Cervavac creates a new opportunity for widespread access to cancer-preventive vaccination for individuals aged 9 to 26. Consult your healthcare provider about local vaccine availability and the appropriate dosing schedule for your specific age group.
Further reading
For broader context on preventing HPV-related malignancies, visit our Cancer hub.
Live Poll
Should international health agencies prioritize the certification of vaccines developed in emerging economies?
